Posted by Michael Wonder on 06 Mar 2020
Gastric cancer drug Liporaxel nears getting insurance benefit
6 March 2020 - Daehwa Pharmaceutical’s Liporaxel (paclitaxel), a treatment for advanced, metastatic and local recurrent gastric cancer, has neared winning the health insurance coverage.
Three other drugs also obtained the health insurance review agency’s nod to grant reimbursement. They are Novartis Korea’s allergic asthma treatment Xolair injection/Xolair pre-filled syringe (omalizumab), AbbVie Korea’s moderate to severe plaque psoriasis treatment Skyrizi (risankizumab) and Lilly Korea’s breast cancer drug Verzenio (abemaciclib).
